|Bid||0.0000 x 4000|
|Ask||0.0000 x 3000|
|Day's Range||2.5100 - 2.6400|
|52 Week Range||1.0400 - 5.9800|
|Beta (5Y Monthly)||2.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 08, 2021 - Nov. 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.29|
Infinity Pharmaceuticals (NASDAQ: INFI) got off to a market-beating start this week as its shares zoomed 3.8% higher Monday, on the back of new analyst coverage that made an extremely bullish case for investing in the biotech. H.C. Wainwright's Michael King Jr. is the prominent new Infinity bull. King points out that the company's lead pipeline candidate, the cancer treatment eganelisib, "has shown compelling activity both as a single agent as well as in combination with commonly used immune checkpoint inhibitors."
Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
CAMBRIDGE, Mass., September 13, 2021--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that the Company will participate in Oppenheimer’s Fall Healthcare Life Sciences and MedTech Summit and at the 3rd Annual Macrophage-directed Therapies Summit.